Venmax Drugs & Pharmaceuticals Fair Value
Venmax Drugs & Pharmaceuticals fair value. Venmax Drugs & Pharmaceuticals (VENMAX) average fair value is ₹17.69 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹14.44 (+22.48%), fair value range ₹7.62–₹34.12. Explore Venmax Drugs & Pharmaceuticals intrinsic price to estimate fundamental worth using multiple valuation models.
Fair Value Analysis Export
VENMAX Fair Value vs Current Price — Valuation Summary
VENMAX average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. For live price and a broader fundamental view, visit Venmax Drugs & Pharmaceuticals share price screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
VENMAX Fair Value Analysis — Data Sources & Coverage
Venmax Drugs & Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used. Check VENMAX market cap trends to track the company's total market size over time.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
VENMAX vs Healthcare Sector Peers — P/E, P/B & Market Cap
Venmax Drugs & Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.